Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(5)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnsOeKh|ryP MlT5OFjDqGh? NXvF[oox[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| MmOyNlY{PTB3NkW=
NP69 NFPyfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNzLk[5xtEzNjV2IN88US=> NF7kPGMzPjJ3MkW3OS=>
NP460 M3PESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LjPGlEPTB;MkKuPFXDuTFwMUig{txO MXKyOlI2OjV5NR?=
C666-1 NXvTWGpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nXfGlEPTB;MUmuPVXDuThwOUOg{txO NVHTUFV{OjZ{NUK1O|U>
C666-1 NXzld5BIS2WubDDWbYFjcWyrdImgRZN{[Xl? MVOxNEDDvU1? MWW0PEBp Mkm2SG1UVw>? M2PyUpNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= MXOyOlI2OjV5NR?=
C666-1  M4rSSmZ2dmO2aX;uJGF{e2G7 NVXjcGd{OTBiwsXN M1\KVlI1KGh? MnvmSG1UVw>? MXThZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> MorBNlYzPTJ3N{W=
C666-1 NVLaeYlOSXCxcITvd4l{KEG|c3H5 NVKzUGY5OTBiwsXN MVW0PE84OiCq MofFSG1UVw>? M2rve5NmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> M{XaTlI3OjV{NUe1
A549 NGnuPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PTfVI1KGh? M2DrNmlEPTB;MUeuOlghyrFiND61NkDPxE1? Ml74NlYyOjV{M{C=
A549-NTC NV;PcGxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\pOVI1KGh? MnzRTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? NG[xclUzPjF{NUKzNC=>
A549-920 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PsbFI1KGh? MWDJR|UxRTN|Lki1JOKyKDRwOESg{txO NXzHbXpVOjZzMkWyN|A>
CRL-5908 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPYNlQhcA>? NH7YflBKSzVyPUO4MlcyKMLzIEKuOFMh|ryP M1nBbVI3OTJ3MkOw
L6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3PVExyqEQvF5CpC=> M4\keVI1NzR6L{eyJIg> MV3EUXNQ NYnyU|FEcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MWGyOVg4OTd7NB?=
C2C12 M3Hofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sXlExyqEQvF5CpC=> M{T0S|I1NzR6L{eyJIg> MV\EUXNQ NY\ufXNOcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MVSyOVg4OTd7NB?=
MCF-7  NGG3enhHfW6ldHnvckBCe3OjeR?= M{izUVExyqEQvF2= MonqSG1UVw>? NY\Pc|F7cW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi MlTSNlU4ODJ5MEO=
DU4475  NGWzWmJHfW6ldHnvckBCe3OjeR?= M4XFT|UwOTBxMkCg{txO NYfHb5JWOjUEoHi= M2HrOIRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> NWnPW|hmOjV3NEexO|Q>
SMMC-7721 M2HLUmZ2dmO2aX;uJGF{e2G7 NVzxTXQ5OTBizszN NF3WO5Y1QCCq MVPEUXNQ Mnm2Z4F2e2W|IFTORUBFW0JiZHHtZYdm MUmyOVU1PDN4MR?=
SMMC-7721 M{nzfWZ2dmO2aX;uJGF{e2G7 NWLiVZZTOTBizszN MYi0PEBp NGXKVZRFVVOR M1fITYlv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> NWHRd5pjOjV3NESzOlE>
SMMC-7721 NWLDPHA2TnWwY4Tpc44hSXO|YYm= MlXBNVAh|ryP MljCOFghcA>? MlztSG1UVw>? M3vSOYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> NVTRTos{OjV3NESzOlE>
SMMC-7721 NWHZWIZqTnWwY4Tpc44hSXO|YYm= MkLXNVAh|ryP NFP4R48{PiCq M{Pj[2ROW09? NHnaZ45k[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? NHO0S5ozPTV2NEO2NS=>
MCF-7 NU[xe|F6TnWwY4Tpc44hSXO|YYm= NYnYZ2RUOTEEoN88US=> M3K0d|AuOjRiaB?= MVLpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? NYCyfWlmOjV2OEKzO|M>
OVCAR10 NUj2N5c1TnWwY4Tpc44hSXO|YYm= NV22fVk{OTEEoN88US=> M33TWlIycMLi NFrBb2VFVVOR MmL5bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> Mn3yNlU1OjZ3NEi=
NCI-H23 MWXGeY5kfGmxbjDBd5NigQ>? NH3OSIEyOMLizszN NGntfFQzOWkEoB?= NGDM[JpFVVOR NX;U[4txcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MlHxNlU1OjZ3NEi=
A2780 MX;GeY5kfGmxbjDBd5NigQ>? MnLCNVDDqM7:TR?= NX61[FU{OjGqwrC= NUfIe4V7TE2VTx?= NYTTZopkcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? MnqxNlU1OjZ3NEi=
NCI-H23 MYDGeY5kfGmxbjDBd5NigQ>? NXvWbnZROTEEoN88US=> NWHQV2dTOjGqwrC= MVLEUXNQ MXrk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MmPwNlU1OjZ3NEi=
A2780 NWXFdXpbTnWwY4Tpc44hSXO|YYm= MVSxNOKh|ryP MVOyNYjDqA>? NFq1c5FFVVOR MkPJ[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= NYfKdW5rOjV2Mk[1OFg>
HCT116  NF7Ob4FHfW6ldHnvckBCe3OjeR?= MmjNNVAhyrWP NX;ofFZNOjRiaB?= NWey[3BD[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 M{\2dlI2OzhyMEW1
MCF-10CA1a NUPqRmVrTnWwY4Tpc44hSXO|YYm= NWXpXYFlOTEEoN88US=> NXK4N|JqPDhiaB?= M3S4[GROW09? M4rkVIlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? NVnRXXNZOjV{NUe3Nlk>
MCF-10A1  MW\GeY5kfGmxbjDBd5NigQ>? NInSbIMyOMLizszN M2PyPVI1NzR6IHi= MnXlSG1UVw>? NF;XWI9qdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? NYnndWZKOjV{NUe3Nlk>
MCF-10CA1a MlzTSpVv[3Srb36gRZN{[Xl? NYL2WGpTOTEEoN88US=> M{\DVVI1KGh? M2rz[2ROW09? Ml;M[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? MmK0NlUzPTd5Mkm=
MCF-10CA1a NWqxO5kxTnWwY4Tpc44hSXO|YYm= NHnCSYcyOMLizszN MYeyOEBp MXnEUXNQ M13YeolvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MVyyOVI2Pzd{OR?=
SK-BR-7 M2PweWZ2dmO2aX;uJGF{e2G7 MUSxNOKh|ryP MYmyOEBp NXTJRnhjTE2VTx?= NXjvS5locW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NYrBd2VKOjV{NUe3Nlk>
SUM102PT M3v4TWZ2dmO2aX;uJGF{e2G7 MUWxNOKh|ryP MYiyOEBp Mn7jSG1UVw>? NF71WWVqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M3r1N|I2OjV5N{K5
RAW 264.7 MnXMSpVv[3Srb36gRZN{[Xl? M1OxTVExyqEQvF2= MnLlN|AhdWmw M3ntN5Bz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NUDOU5VbOjVzN{K1OFc>
RAW 264.7 M4DVU2Z2dmO2aX;uJGF{e2G7 M3S5TFExyqEQvF2= MXmzNEBucW5? NFLGVFlz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 NHi2VlQzPTF5MkW0Oy=>
RAW 264.7 MXLGeY5kfGmxbjDBd5NigQ>? MnXNNVDDqM7:TR?= NH30ZZg{OCCvaX6= M1nq[4lvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> NI\mOYIzPTF5MkW0Oy=>
MCF7  MonCR4VtdCCYaXHibYxqfHliQYPzZZk> MY[yMlUhyrWP MX:1JIQ> NIOyfXdFVVOR M17HZZNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= M1:wdFI2ODh3OUCy
MCF7  M{i1N2Z2dmO2aX;uJGF{e2G7 NVmz[pNmOi53INM1US=> NYHnVYMyPDhiaB?= MUXEUXNQ M2TReIRm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ NFrrTZkzPTB6NUmwNi=>
ACHN M{[zOmNmdGxiVnnhZoltcXS7IFHzd4F6 NYPoWZg3OC53LUGwJO69VQ>? MUewMVYh\A>? NHjhXlhFVVOR MnTMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHrMcoQzPTB4N{e4Oy=>
Caki-2 M2fNVGNmdGxiVnnhZoltcXS7IFHzd4F6 M4\yOVAvPS1zMDFOwG0> MojqNE03KGR? NVvYcYZCTE2VTx?= MnfCbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlrCNlUxPjd5OEe=
A498 NV20SnRvS2WubDDWbYFjcWyrdImgRZN{[Xl? NHLXc5YxNjVvMUCg{txO M1HZdVAuPiCm Ml3SSG1UVw>? NU\O[GN6cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF;PdoMzPTB4N{e4Oy=>
115 MmD3R4VtdCCYaXHibYxqfHliQYPzZZk> MmLoNE42NTFyIN88US=> M{jGSVAuPiCm Ml[4SG1UVw>? MlTWbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2Xs[|I2ODZ5N{i3
117 M2DEWWNmdGxiVnnhZoltcXS7IFHzd4F6 Mo\5NE42NTFyIN88US=> NVntO4wzOC14IHS= NYjteWk4TE2VTx?= NILxOmJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml7uNlUxPjd5OEe=
ACHN MnKxSpVv[3Srb36gRZN{[Xl? Mk\pNE42NzFxNTFOwG0> MYO0PEBp MVHEUXNQ MnHLcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M2Txb|I2ODZ5N{i3
Caki-2 M3frVGZ2dmO2aX;uJGF{e2G7 Moq4NE42NzFxNTFOwG0> M1OwTFQ5KGh? NF\XfFdFVVOR MYHs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MUCyOVA3Pzd6Nx?=
A498 Mlz2SpVv[3Srb36gRZN{[Xl? M2PaU|AvPS9zL{Wg{txO M2TDU|Q5KGh? MXzEUXNQ MnT5cIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NHLrVnQzPTB4N{e4Oy=>
115 MojvSpVv[3Srb36gRZN{[Xl? MoXwNE42NzFxNTFOwG0> Ml;SOFghcA>? M4n0UmROW09? MlvNcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NWWxfGw{OjVyNke3PFc>
ACHN MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK1JO69VQ>? MkfEOFghcA>? M4nrRmROW09? M1fFc4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MYWyOVA3Pzd6Nx?=
Caki-2 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nJclUh|ryP NFPMXoM1QCCq NXnsRZlCTE2VTx?= M1HyW4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NXzkTm54OjVyNke3PFc>
A498 M2ntcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2zOUDPxE1? NXrSTVZPPDhiaB?= NHrQU41FVVOR MYHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NIHvU3czPTB4N{e4Oy=>
115 NE\ZSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH0dmo2KM7:TR?= NGTGNos1QCCq NVHWN3lITE2VTx?= NUDBSHhYcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M165UlI2ODZ5N{i3
ACHN NHnDeFlHfW6ldHnvckBCe3OjeR?= MmjiOUDPxE1? NF3IPW41QCCq NHXmZ4hFVVOR NEjRbYpqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MknsNlUxPjd5OEe=
Caki-2 M3\XPWZ2dmO2aX;uJGF{e2G7 M3vB[|Uh|ryP MoPvOFghcA>? NGjZXpFFVVOR NXmzPY9RcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NEHU[WMzPTB4N{e4Oy=>
A498 MX\GeY5kfGmxbjDBd5NigQ>? M4XBWVUh|ryP NHr0c|Q1QCCq MWDEUXNQ M4X6Uolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NIridZIzPTB4N{e4Oy=>
115 NH;5fJlHfW6ldHnvckBCe3OjeR?= MlHuOUDPxE1? NV\6d25ZPDhiaB?= MkH1SG1UVw>? MWfpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NXjaXHlbOjVyNke3PFc>
MOLM-13 MVvGeY5kfGmxbjDBd5NigQ>? MWm2xsDPxE1? NXjlVllmOC16IHi= NIP4c4tFVVOR NGi2TFZqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwOVMtKE2GTUKsJJAzOSCjbnSgZYNmfHmuYYTl[EBxPTN? MXOyOFg5PTB6Mh?=
MOLM-13 NE\v[mZHfW6ldHnvckBCe3OjeR?= MnHFOuKh|ryP NF;YfHY3KGh? M3;ZVmROW09? MYDlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly NWXVdVByOjR6OEWwPFI>
HepG2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX6V|g4OiCq MUfEUXNQ NHr5SmJKSzVyPUO1Mlg3KMLzIEKuPUDPxE1? MlviNlQ5QDR6MEm=
HepG2/As NHz1RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3NkBp MlzJSG1UVw>? Mln5TWM2OD14OD6xN{DDuSB7Lk[g{txO MUGyOFg5PDhyOR?=
SMMC7721 NFjj[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXqV3k4OiCq MoDvSG1UVw>? MYLJR|UxRTNzLkK4JOKyKDRwMjFOwG0> MmHtNlQ5QDR6MEm=
SMMC7721/Ac NXPHWllJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXIO|IhcA>? MoLqSG1UVw>? Mlq4TWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? MYqyOFg5PDhyOR?=
Huh-7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp NYfhfodJTE2VTx?= MkLOTWM2OD1|Mz65OkDDuSB|Lkmg{txO Mle3NlQ5QDR6MEm=
Hep3B MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml60O|IhcA>? Mkj5SG1UVw>? MYPJR|UxRTJyLkG4JOKyKDFwOESg{txO NWXmeZp[OjR6OES4NFk>
HepG2 M3LV[WFxd3C2b4Ppd{BCe3OjeR?= MX;pcoR2[2W|IHHwc5B1d3Orcx?= MknNNlQ5QDR6MEm=
SMMC7721 M4fxfmFxd3C2b4Ppd{BCe3OjeR?= MUnpcoR2[2W|IHHwc5B1d3Orcx?= NX7lT2V6OjR6OES4NFk>
Huh-7 M3zmcGFxd3C2b4Ppd{BCe3OjeR?= M1;PU4lv\HWlZYOgZZBweHSxc3nz NFfHblczPDh6NEiwPS=>
Hep3B M3;Q[GFxd3C2b4Ppd{BCe3OjeR?= NXrXZ3NWcW6mdXPld{BieG:ydH;zbZM> NHrUe2EzPDh6NEiwPS=>
U2OS  M2fX[2Z2dmO2aX;uJGF{e2G7 NXfEWI1pOjBizszN MUSyOEBp MXjpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ MnHHNlQ5Pjd{NUm=
AML2 NHrqOm9CeG:ydH;zbZMhSXO|YYm= Mn3RNk8yOCEQvF2= MXOyOE81QCCq MmDhbY5lfWOnczDhdI9xfG:|aYO= MXSyOFY2QTd2OR?=
MOML13 NG\KbpVCeG:ydH;zbZMhSXO|YYm= NWrYT3JTOi9zMDFOwG0> MnPpNlQwPDhiaB?= NUjFS4pScW6mdXPld{BieG:ydH;zbZM> MoruNlQ3PTl5NEm=
AML2 M2LBZmZ2dmO2aX;uJGF{e2G7 MoXCNVDPxE1? NF3G[2wzNzRiaB?= NGnnW2dqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NGjXWlYzPDZ3OUe0PS=>
AML3 M{PF[WZ2dmO2aX;uJGF{e2G7 M{\0Z|Ex|ryP NVvYcXlQOi92IHi= M33NS4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M{KzW|I1PjV7N{S5
MOML13 MVnGeY5kfGmxbjDBd5NigQ>? Mnj2NVDPxE1? MWmyM|QhcA>? MWPpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MYeyOFY2QTd2OR?=
BeWo NEe2cG1HfW6ldHnvckBCe3OjeR?= NILuNlU{OCEEtV2= MYCyOEBp NF7XZ2ZqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> MXWyOFQ6QDF3NB?=
BeWo M3fYdmFxd3C2b4Ppd{BCe3OjeR?= MoHJN|AhyrWP MljONlQhcA>? MnzTbY5kemWjc3XzJIFxd3C2b4Ppdy=> NYqyU2ZPOjR2OUixOVQ>
OCI MUTGeY5kfGmxbjDBd5NigQ>? NEi4[5AyOCEQvF2= M2fzelI1KGh? MU\1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? NIfEUZczPDR5M{W2Ni=>
MOLM M4LXVGZ2dmO2aX;uJGF{e2G7 MWmxNEDPxE1? M1;zO|I1KGh? M1jUV5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NGK3XpIzPDR5M{W2Ni=>
U2OS  MoTPSpVv[3Srb36gRZN{[Xl? MUOyNEDPxE1? NGn4bGMzPCCq MkjTbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? Mk\wNlQ{PjZyMEe=
RKO NIjPRXJHfW6ldHnvckBCe3OjeR?= NXLQXmQxOjBizszN M4jJVlI1KGh? NIPmUY5qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M1PaU|I1OzZ4MEC3
U2OS  M2r0bmZ2dmO2aX;uJGF{e2G7 M4jRfVIxKM7:TR?= NX3HXHE{OjRiaB?= NWLPOY9wcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> NFrifZUzPDN4NkCwOy=>
RKO NX\IXpFQTnWwY4Tpc44hSXO|YYm= MnzsNlAh|ryP MXyyOEBp M3ToVYlv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u M4Lsb|I1OzZ4MEC3
SMMC-7721  MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWSxMlI2NTJyIN88US=> MnvpNlQwPDhxN{KgbC=> NFLjNG1FVVOR M4LHeYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MWSyOFI5PjNzMh?=
HuH-7 NIrlUGdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mk[yNU4zPS1{MDFOwG0> NYDG[VdiOjRxNEivO|IhcA>? M1W5dmROW09? NVzhUG9PcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MYWyOFI5PjNzMh?=
SMMC-7721  MnXzRZBweHSxc3nzJGF{e2G7 M1nwbFIxKM7:TR?= MkXXOFghcA>? MV;EUXNQ MnTibY5lfWOnczDhdI9xfG:|aYO= NGT4RXgzPDJ6NkOxNi=>
HuH-7 MmXWRZBweHSxc3nzJGF{e2G7 NVj0d4RLOjBizszN NX\lWpFmPDhiaB?= Mn:xSG1UVw>? Mlm2bY5lfWOnczDhdI9xfG:|aYO= M3L3WlI1Ojh4M{Gy
SMMC-7721  NF3JUHhHfW6ldHnvckBCe3OjeR?= MmHPNVAh|ryP MWCzOkBp MYXEUXNQ NFjCe4dld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? MUmyOFI5PjNzMh?=
HuH-7 MlfoSpVv[3Srb36gRZN{[Xl? NFPucHMyOCEQvF2= NWj2WmJ{OzZiaB?= NV73TVlHTE2VTx?= MUfkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MVGyOFI5PjNzMh?=
AT2 NGjxNGxHfW6ldHnvckBCe3OjeR?= M3jGXlUwOTBizszN MVjs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MoTjNlQzPDB{MEO=
REH NELTfodHfW6ldHnvckBCe3OjeR?= M1G2eFUwOTBizszN MWDs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MnzpNlQzPDB{MEO=
UoCB6 MUDGeY5kfGmxbjDBd5NigQ>? MU[1M|ExKM7:TR?= M1zNfYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M{PRSlI1OjRyMkCz
AT2 NWLTRmV4S2WubDDWbYFjcWyrdImgRZN{[Xl? M1zuUVAuOjVizszN NVPST4t6cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MUKyOFI1ODJyMx?=
REH NFTLWZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlzWNE0zPSEQvF2= M1\IZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3r2XlI1OjRyMkCz
UoCB6 NHXyV25E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEnBbG4xNTJ3IN88US=> NEfEdW5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYjUNGd3OjR{NECyNFM>
A2780 NUXhXVZLTnWwY4Tpc44hSXO|YYm= NX\2W21SPS9zMD:yNEDPxE1? NFX5PXgzPCCq M1PzRZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NF[0e28zPDF|NkG0Oy=>
H460 Mo\BSpVv[3Srb36gRZN{[Xl? MlHqOU8yOC9{MDFOwG0> NX7OeYRxOjRiaB?= MojzeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NHTZTIUzPDF|NkG0Oy=>
Lovo  MVHGeY5kfGmxbjDBd5NigQ>? MonYOU8yOC9{MDFOwG0> NIC3VFkzPCCq M2G4UJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi M4fkVVI1OTN4MUS3
A2780 NGjQRZRCeG:ydH;zbZMhSXO|YYm= NGjWc5I2NzFyL{KwJO69VQ>? M3m3VlI1KGh? NHe5[2dmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? MWCyOFE{PjF2Nx?=
H460 MkLPRZBweHSxc3nzJGF{e2G7 Mn24OU8yOC9{MDFOwG0> NIT6d5EzPCCq M1myXoVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NHzuXnUzPDF|NkG0Oy=>
Lovo  MmjwRZBweHSxc3nzJGF{e2G7 Ml3IOU8yOC9{MDFOwG0> NXLQempKOjRiaB?= MnOz[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> MlTkNlQyOzZzNEe=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2シグナル伝達経路

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID